Pfizer, BioNTech release preclinical data, talk with EU about COVID-19 vaccine
Preclinical data have demonstrated the ability of BNT162b2, Pfizer and BioNTech's COVID-19 vaccine, to protect against infection. The companies are also in discussions to provide Europe with 200 million doses of the candidate.
Intravacc receives NIH award to develop enterovirus D68 vaccine
Intravacc has been awarded a $9.4 million contract from the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health (NIH), to develop a prophylactic vaccine against enterovirus D68.
Thermo Fisher to manufacture Inovio's COVID-19 vaccine
Thermo Fisher Scientific has signed a letter of intent to manufacture Inovio's DNA COVID-19 vaccine candidate, INO-4800.
Exelixis enters collaborations for antibody drug conjugates
Exelixis has entered into two separate partnerships with Catalent and NBE Therapeutics for the discovery and development of multiple antibody-drug conjugates for oncology applications to build out the pipeline for Cabometyx, its flagship product.
Biopharma CEOs pledge commitment to safe vaccines
The CEOs from nine biopharmaceutical companies have pledged to remain committed to upholding the integrity of the scientific process as they work toward global regulatory filings and approvals for COVID-19 vaccines.
MD Anderson, Xencor partner on XmAb candidates
The University of Texas MD Anderson Cancer Center and Xencor have entered a strategic collaboration to study investigational treatments for cancers. Together, they will collaborate to design and execute clinical studies with Xencor's X monoclonal antibody (XmAb) drug candidates.
Kite submits BLA for CAR-T in non-Hodgkin lymphomas
Kite, a Gilead company, has submitted a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration for axicabtagene ciloleucel (Yescarta) for the treatment of relapsed or refractory follicular lymphoma or marginal zone lymphomas after two or more prior therapies.
AbbVie, I-Mab partner on cancer mAb, I-Mab raises $418M
AbbVie and I-Mab have signed a global collaboration agreement for the development and commercialization of lemzoparlimab (TJC4), an anti-CD47 monoclonal antibody (mAb).
Magenta to explore targeted gene editing to cure HIV
Clinical-stage biotechnology company Magenta Therapeutics has joined a broad-based research effort to explore gene- and cell-based approaches to cure HIV.
Lodo Therapeutics acquires Hibiskus BioPharma
Informatics-based drug discovery company Lodo Therapeutics has acquired Hibiskus BiopPharama to expand its cancer compound pipeline.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter